Comparative Pharmacology
Head-to-head clinical analysis: AMIKIN versus GVS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIKIN versus GVS.
AMIKIN vs GVS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis.
GVS is not a recognized drug. No mechanism of action available.
15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day
1 mg IV bolus every 3 minutes up to 3 doses as needed for status epilepticus; max total dose 3 mg.
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 30-90 hours in ESRD.
Terminal half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Renal: >90% unchanged in urine via glomerular filtration; biliary/fecal: <1%.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other.
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic